Latest News and Press Releases

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Biopharmaceutical CMO & CRO Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The...

Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Purvalanol A (CDK Inhibitor) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Purvalanol A (CDK Inhibitor) market has...

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and...

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Adrenocortical Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The adrenocortical carcinoma market is on a...

KNOXVILLE, Tenn., April 02, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent preclinical...

AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune to host symposium highlighting Precision Prevention approach to Parkinson's...

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody-drug Conjugates (ADCs) in Oncology - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering.This report...

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitorNLRP3 inhibitors are a major new class of...

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of CD47 and SIRP-alpha Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...

Dewpoint Therapeutics selects a first-in-class small molecule development candidate for multiple cancers in which MYC dependence is a central driver.